GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » EV-to-FCF

Orphazyme AS (CHIX:ORPHAC) EV-to-FCF : 0.02 (As of Jun. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Orphazyme AS's Enterprise Value is kr-14.76 Mil. Orphazyme AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was kr-721.82 Mil. Therefore, Orphazyme AS's EV-to-FCF for today is 0.02.

The historical rank and industry rank for Orphazyme AS's EV-to-FCF or its related term are showing as below:

CHIX:ORPHAc's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 5.935
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-22), Orphazyme AS's stock price is kr8425.00. Orphazyme AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was kr0.000. Therefore, Orphazyme AS's PE Ratio for today is N/A.


Orphazyme AS EV-to-FCF Historical Data

The historical data trend for Orphazyme AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS EV-to-FCF Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-FCF
Get a 7-Day Free Trial -9.11 -1.98 -4.24 -3.07 -0.89

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.07 - -0.89 -

Competitive Comparison of Orphazyme AS's EV-to-FCF

For the Biotechnology subindustry, Orphazyme AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's EV-to-FCF falls into.



Orphazyme AS EV-to-FCF Calculation

Orphazyme AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-14.757/-721.822
=0.02

Orphazyme AS's current Enterprise Value is kr-14.76 Mil.
Orphazyme AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-721.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (CHIX:ORPHAc) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Orphazyme AS's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8425.00/0.000
=N/A

Orphazyme AS's share price for today is kr8425.00.
Orphazyme AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Orphazyme AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines